Tags

Type your tag names separated by a space and hit enter

Secondary prevention of coronary artery disease with omega-3 fatty acids.
Am J Cardiol. 2006 Aug 21; 98(4A):61i-70i.AJ

Abstract

Omega-3 fatty acid therapy is a promising intervention for the secondary prevention of coronary artery disease (CAD). Omega-3 fatty acids have properties that promote atherosclerotic plaque stability and decrease the incidence of ischemia-driven cardiac arrhythmias. A large number of clinical trials conducted in patients with CAD or prior myocardial infarction (MI) have examined hard cardiovascular end points, including total mortality, cardiovascular mortality, sudden death, and nonfatal MI. Several intermediate cardiovascular end-point studies have also examined whether ventricular arrhythmias can be suppressed in patients with implantable cardioverter defibrillators (ICDs). Significant reductions in total mortality and sudden death--20% to 50%--have been found in studies using doses of 0.85 to 4.0 g/day, with treatment durations from 12 to 42 months. Favorable trends toward reduction in the incidence of arrhythmic events have been demonstrated in some, but not all, ICD studies. Omega-3 fatty acid therapy shows a general positive trend toward benefit in reducing life-threatening events after MI and in patients with ICDs who have ischemic arrhythmias. Results of the recent Japan EPA Lipid Intervention Study (JELIS) in a large cohort (N = 18,645) of Japanese men and women suggest significant benefits in the reduction of unstable angina and nonfatal coronary events. The totality of evidence supports a strong role for omega-3 fatty acids derived from fish oil in secondary prevention through a presumptive role as an antiarrhythmic agent and through an ability to promote plaque stabilization.

Authors+Show Affiliations

Department of Medicine, Office of Health Promotion and Disease Prevention, Emory University School of Medicine, Atlanta, Georgia 30303, USA. tjaco02@emory.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16919518

Citation

Jacobson, Terry A.. "Secondary Prevention of Coronary Artery Disease With Omega-3 Fatty Acids." The American Journal of Cardiology, vol. 98, no. 4A, 2006, pp. 61i-70i.
Jacobson TA. Secondary prevention of coronary artery disease with omega-3 fatty acids. Am J Cardiol. 2006;98(4A):61i-70i.
Jacobson, T. A. (2006). Secondary prevention of coronary artery disease with omega-3 fatty acids. The American Journal of Cardiology, 98(4A), 61i-70i.
Jacobson TA. Secondary Prevention of Coronary Artery Disease With Omega-3 Fatty Acids. Am J Cardiol. 2006 Aug 21;98(4A):61i-70i. PubMed PMID: 16919518.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Secondary prevention of coronary artery disease with omega-3 fatty acids. A1 - Jacobson,Terry A, Y1 - 2006/05/30/ PY - 2006/8/22/pubmed PY - 2006/9/29/medline PY - 2006/8/22/entrez SP - 61i EP - 70i JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 98 IS - 4A N2 - Omega-3 fatty acid therapy is a promising intervention for the secondary prevention of coronary artery disease (CAD). Omega-3 fatty acids have properties that promote atherosclerotic plaque stability and decrease the incidence of ischemia-driven cardiac arrhythmias. A large number of clinical trials conducted in patients with CAD or prior myocardial infarction (MI) have examined hard cardiovascular end points, including total mortality, cardiovascular mortality, sudden death, and nonfatal MI. Several intermediate cardiovascular end-point studies have also examined whether ventricular arrhythmias can be suppressed in patients with implantable cardioverter defibrillators (ICDs). Significant reductions in total mortality and sudden death--20% to 50%--have been found in studies using doses of 0.85 to 4.0 g/day, with treatment durations from 12 to 42 months. Favorable trends toward reduction in the incidence of arrhythmic events have been demonstrated in some, but not all, ICD studies. Omega-3 fatty acid therapy shows a general positive trend toward benefit in reducing life-threatening events after MI and in patients with ICDs who have ischemic arrhythmias. Results of the recent Japan EPA Lipid Intervention Study (JELIS) in a large cohort (N = 18,645) of Japanese men and women suggest significant benefits in the reduction of unstable angina and nonfatal coronary events. The totality of evidence supports a strong role for omega-3 fatty acids derived from fish oil in secondary prevention through a presumptive role as an antiarrhythmic agent and through an ability to promote plaque stabilization. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/16919518/Secondary_prevention_of_coronary_artery_disease_with_omega_3_fatty_acids_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(05)02191-0 DB - PRIME DP - Unbound Medicine ER -